CJC-1295 NO DAC - Mod GRF (1-29) - 5 mg

CJC-1295 NO DAC - Mod GRF (1-29) - 5 mg

39,90 €

Modified GRF is a truncated peptide analogue of growth hormone releasing hormone (GHRH).

It has been shown to have the following effects:

- Improves muscle repair and growth

- Accelerates wound healing

- Strengthens bones

- Increases fat burning

- Improves metabolism.

- It may also have beneficial effects on blood sugar regulation and the immune system.



Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.9 g/mol
CAS: 863288-34-0
Peptide Purity: greater than 98%
Other details: No TFA Salt
Storage: Lyophilized peptide must be stored at -20°C and peptide solution at 4°C.

CJC-1295 DAC has low oral and excellent subcutaneous bioavailability.



CJC-1295 Without DAC is a 30 amino acid petite hormone that is commonly referred to as Growth Hormone Releasing Hormone (GHRH). Upon creation, CJC-1295 Without DAC's major function was to boost the synthesis of protein and increase muscle tissue growth, among other benefits.CJC-1295 Without DAC is also crucial in assisting in speeding up recovery from injuries, boosting the immune system, cutting down body fat, increasing bone density, and repairing cells of the skin and organs.

When you encounter CJC-1295 Without DAC, the substance in question is MOD GRF 1-29. This peptide is just a simplified version of the original GRF 1-29 peptide commonly known as Sermorelin. The original GRF 1-29 has an extremely short half-life, which is the reason chemists modified it to extend its biological activity and reduce the metabolic clearance. Even with the modification of the peptide having produced a greater peptide bond, there is still a need for the average user to inject with a GRHP two or three times daily to achieve optimal effectiveness and release endogenous growth hormone.

The introduction of DAC to CJC 1295 enabled a bigger greater possibility for utilization of smaller Growth Hormone (GH) pulses, which, when combined with a GRHP, activates growth hormone stores to release throughout the day and night. The introduction of the DAC component also increased the peptide's half-life to about a week and steadied blood levels after injection.

For persons who prefer to use a shorter dose of GH release, the use of MOD GRF 1-29 or the CJC without DAC will give optimal results. On the other hand, if you prefer fewer injections while still striving to unleash the growth hormone stores, an injection of CJC with DAC one to two times a week along with the daily GHRP injection will maximize the GH release.

CJC 1295 DAC versus CJC 1295 no DAC

The two are both GHRHs. They have the same function in the human body with the only difference being in their half-life span. Modified GRF1-29(CJC 1295 No DAC) and Sermorelin have a short-acting half-life of 30 minutes, while CJC 1295 DAC has a half-life of up to eight days. According to some scientists' reports, modified GRF 1-29 and Sermorelin are more natural since they produce a short pulse of Human Growth Hormone.



A. Volpe et al., "Clinical use of growth hormone-releasing factor for induction of superovulation" [PubMed]

M. Ionescu et al., "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog" [PubMed]

S.L. Teichman et al., "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults" [PubMed]

M. Alba et al., "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse" [PubMed]

M. Alba et al., "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse" [American Journal of Physiology-Endocrinology and Metabolism]

L. Sackmann-Sala et al., "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects" [PubMed]



This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

All product information provided on this website is for informational and educational purposes only.

Fiche technique


Les clients qui ont acheté ce produit ont également acheté...